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Abstract
Introduction: The role of matrix metalloproteinases (MMPs) in type 2 diabetes
mellitus (DM) is not clear as increased activation of MMPs in the vasculature
contrasts with decreased activity of MMPs in the kidneys, contributing to
development of nephropathy.
Material and methods: We measured serum MMP-2 and MMP-9 in 22 subjects
with type 2 DM age (mean ± SD) 56.7 ±16.8 years, BMI 31.8 ±4.6 kg/m2, HbA1c
8.45 ±1.78% and in 32 controls, age 39.2 ±16.0 years, BMI 35.2 ±8.5 kg/m2. In 15
subjects with 2 DM we also measured MMP-2 and MMP-9 at discharge from
hospital and after 3 months (n = 8). In controls, MMP-2 and -9 were also
measured during 75 g oral glucose tolerance test (OGTT).
Results: Concentrations of MMP-2 and MMP-9 were lower in subjects with type
2 DM (219 ±62 ng/ml vs. 305 ±63 ng/ml and 716 ±469 ng/ml vs. 1285 ±470 ng/ml,
for MMP-2 and MMP-9, respectively, p < 0.05). MMP-9 concentrations fell at 120
min of OGTT from 1675 ±372 ng/ml to 1276 ±422 ng/ml (p < 0.05). In diabetic
subjects there was a correlation between MMP-9 and HbA1c (r = 0.51, p < 0.05).
In subjects with diabetes there was a fall of HbA1c from 9.77 ±1.76% to 8.36
±1.54% (p < 0.01), at three months post-discharge. There was no difference in
MMP-2, but there was a fall in MMP-9 at three months post-discharge in
comparison to concentrations observed at admission (854 ±560 ng/ml vs. 500
±235 ng/ml, p = 0.02). 
Conclusions: Matrix metalloproteinases in type 2 and MMP-9 concentrations
were lower in subjects with 2 DM than in non-diabetic controls. Regulation of
MMPs appears to be complex as hyperglycaemia during OGTT results in
a decrease in MMP-9, while chronic hyperglycaemia, reflected by HbA1c,
correlates with MMP-9 concentrations in subjects with 2 DM. 
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Introduction
Abnormal carbohydrate metabolism is an important and still growing
social problem. For some years it has been recognised that cardiovascular
complications are the leading cause of increasing premature mortality in
patients with type 2 diabetes [1-4]. Despite considerable progress in
elucidation of the mechanisms leading to development of diabetic
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angiopathy, our understanding of the precise events
involved in this process, including abnormalities in
vascular remodelling, is still far from complete.
Recently it has been proven that matrix metal  -
loproteinases (MMPs) play an important role in
atherosclerosis and rebuilding of the vascular 
wall [5].
Matrix metalloproteinases are a family of zinc-
binding proteolytic enzymes that normally remodel
the extracellular matrix and pathologically attack
substrates as part of an inflammatory response.
Increased activity of MMPs has been reported in
numerous disease processes including tumour
growth, arthritis and cardiovascular disease.
Increased matrix degradation by MMPs within the
atherosclerotic plaque has been implicated as one
of the key factors that leads to plaque instability,
and consequently to cardiovascular events [6]. The
major MMP species in the myocardium and
vasculature are the gelatinases (MMPs 2 and 9),
MMP-1 (interstitial collagenase) and Mt1-MMP .
Matrix metalloproteinases in type 2 and MMP-9
specifically attack type IV collagen, laminin, and
fibronectin, major components of the basal lamina
around blood vessels [7]. Matrix metalloproteinases
in type 2 diabetes, found in human arteries, have
been implicated in acute myocardial ischaemia and
reperfusion injury [8], and along with MMP-9 play
a major role in myocardial and vascular matrix
remodelling [9]. Furthermore, increased expression
of MMP-9 has been demonstrated in the vulnerable
regions of human atherosclerotic plaques [10].
Metalloproteinases also participate in the formation
and destabilization of the atherosclerotic plaque.
A key role in this phenomenon is linked with
activation of MMP-1, MMP-2, MMP-3, MMP-7 and
MMP-9 within atherosclerotic arteries [11].
Circulatory levels of MMP-2 and MMP-9 are
reported to be raised in patients with acute
coronary syndromes [12]. Increased expression and
activation of MMP-2 and MMP-9 were found in
cerebral ischaemia [13], whilst increased MMP-9
expression has been related to haemorrhagic
transformation of cardio-embolic stroke [14].
In comparison with the general population,
atherosclerosis in diabetic patients manifests
earlier, is more severe and has a more disseminated
character. Moreover, diabetic patients die more
frequently of myocardial infarction, suffer from
recurrent coronary events and are more prone to
the development of heart insufficiency. A reason
for this adverse prognosis could also be related to
disturbed synthesis and activity of MMPs [15].
However, the relationship between MMPs and 
their inhibitors (tissue inhibitors of matrix metallo  -
proteinases – TIMPs) and diabetic angiopathy is less
well defined. Hyperglycaemia directly or indirectly
(e.g., via oxidative stress or advanced glycation
products) might increase MMP expression and
activity in large vessels [16]. On the other hand, low
proteolytic activity of MMPs contributes to diabetic
nephropathy [17, 18], probably via increased
glycation-related activity of TIMP-2, the principal
inhibitor of MMP-2 [19]. Within atherosclerotic
plaques an imbalance between MMPs and TIMPs
may induce matrix degradation, resulting in an
increased risk of plaque rupture. Furthermore,
because MMPs enhance blood coagulability they
may play a role in acute thrombotic occlusion of
vessels and consequent cardiovascular events [20]. 
Despite these data, the role of MMPs in
development of complications of type 2 diabetes
(DM) is not fully understood. Some studies
demonstrate increased activity of MMPs in diabetic
vasculature [16], or skin fibroblasts [21], but
simultaneously there is no evidence of increased
MMP synthesis in venous monocytes in subjects
with type 2 DM [22], while decreased activity of
MMPs (and MMP-2 in particular) has been reported
in diabetic nephropathy [17-19]. 
In our study, we have therefore endeavoured to
compare concentrations of selected matrix
metalloproteinases (MMP-2, MMP-9) in subjects
with diabetes and in non-diabetic controls. We have
also endeavoured to determine the effects of short-
term hyperglycaemia during an oral glucose
tolerance test (OGTT) as well as the effects of
chronic hyperglycaemia on serum concentrations
of MMP-2 and MMP-9.
Material and methods
The study involved 22 subjects with type 2 DM age
(mean ± SD) 56.7 ±16.8 years, BMI 31.8 ±4.6 kg/m2,
HbA1c 8.45 ±1.78% and 32 non-diabetic, normal
glucose tolerance controls, age 39.2 ±16.0 years, BMI
35.2 ±8.5 kg/m2. Normal glucose tolerance was
defined as glucose levels at 120 min of OGTT of no
more than 140 mg/dl – 7.8 mmol/l, and fasting
glucose no more than 110 mg/dl – 6.1 mmol/l. The
design of the study was approved by the Ethical
Committee of The Polish Mother’s Memorial
Research Institute (Poland). Thirty out of 32 controls
were treatment-naI
..
ve, and the remaining two
received antihypertensive medication (ACE
inhibitors and thiazide diuretics). Fifteen out of 
22 subjects with type 2 diabetes were hospitalized
because of unsatisfactory diabetic control, and the
others for investigations of proteinuria (three) or
ischaemic heart disease (four). The latter subjects
had been admitted with chest pains suggestive of
unstable angina, but eventually had no elevation
of troponin concentrations and were referred for
outpatient exercise ECG. Three out of 22 subjects
with type 2 diabetes were treated with insulin,
seven were treated with a combination of
sulfonylurea (Gliclazide) and metformin, two with
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sulfonylurea alone, while the remaining subjects
were treated with either metformin or acarbose, or
a combination of both. All diabetic patients had
normal creatinine; however, seven had evidence of
nephropathy (three with frank proteinuria and four
with microalbuminuria), and one patient also had
pre-proliferative retinopathy. Fourteen patients with
type 2 diabetes had macrovascular complications,
including a history of myocardial infarction 
(5 patients), confirmed ischaemic heart disease 
(6 patients), a history of cerebrovascular accident
with good neurological recovery (2 patients), and
confirmed evidence of carotid artery stenosis 
(1 patient). Twenty out of 22 patients with diabetes
received treatment with ACE inhibitors or
angiotensin receptor blockers, half of them also
received amlodipine (a calcium channel blocker),
eight patients with macrovascular complications
received treatment with statins (simvastatin or
atorvastatin) and aspirin at initial assessment, while
all patients with diabetes were prescribed statins
and aspirin at the time of hospital discharge 
(n = 15). In patients with type 2 diabetes serum
concentrations of MMP-2 and MMP-9 were
measured in the clinic or at admission (n = 22), at
discharge from the hospital (n = 15) and at three
months after discharge (n = 8). In a subgroup of
eight control subjects MMP-2 and MMP-9
concentrations were also measured at 0, 60 
and 120 min of 75 g OGTT. Control subjects 
were recruited either from the Obesity and
Metabolic Syndrome Clinic of The Polish Mother’s
Memorial Research Institute (Poland), or from the
Gastroenterological Clinic in St Alexander Hospital,
Kielce, Poland. In the latter clinic, we recruited
patients who presented with symptoms suggestive
of gastroesophageal reflux, had no evidence of
cardiovascular disease, and subsequently were
found to have no abnormalities on gastroscopy. At
the time of initial assessment control subjects did
not receive any medication that might interfere with
blood concentrations of MMPs. In controls we also
assessed parameters of insulin resistance by means
of HOMA and the Insulin Resistance Index (IRI). The
HOMA index was calculated from fasting glucose
and insulin concentrations according the formula:
Glucose0min (mmol/l) × Insulin0min (μU/ml)/22.5 [23].
Insulin Resistance Index was calculated through
the formula: 2/[1/(INSp × GLYp)] + 1, where INSp
and GLYp are the measured insulin and glycaemic
areas [24]. Insulin Resistance Index is a method
based on changes of glycaemia and insulinaemia
during OGTT, and correlates well with the
euglycaemic hyperinsulinaemic glucose clamp
technique [25]. Serum total MMP-2 and MMP-9
concentrations were measured by ELISA assays
(MMP-2: Human, Biotrak ELISA System; Amersham
Biosciences, intra-assay precision [CV] 6.3%; 
MMP-9 (total): R and D Systems, Minneapolis, USA, 
CV 2.9%).
Statistical analysis
The data were analysed by means of simple
descriptive statistics of location and dispersion and
tests of significance for comparison of distributions
in different groups (parametric or non-parametric
tests depending on the distribution of analysed
variables): the t-test (paired or for independent
groups) and Mann-Whitney or Wilcoxon matched
paired test. Repeated measurements in controls (in
OGTT test) and diabetes (on admission, discharge
and follow-up) were also analysed by Friedman’s
ANOVA by ranks. Associations between covariates
of interest were qualified by means of Pearson 
or Spearman correlations, depending on the
distribution of the analysed variables. Associations
between covariates of interest were qualified by
means of Pearson correlations. In all analyses,
statistical significance was considered achieved at
a value of p ≤ 0.05. All the calculations were derived
by means of Statistica v8.0 software.
Results
Individuals in the control group were significantly
younger (p < 0.01) and non-significantly more obese
(difference in BMI was not significant; p = 0.07).
Demographic characteristics of analysed groups and
comparison of lipid parameters are presented in
Table IA. Twenty-six out of 32 controls were
overweight or obese (81%), 16 (50%) had low HDL
cholesterol (defined as levels below 50 mg/dl for
women and 40 mg/dl for men), 10 (31%) were found
to be hypertensive (BP > 130/85 mmHg), 9 (28%)
had triglycerides above 150 mg/dl, 7 (21%) had
fasting glucose levels between 100 mg/dl and 
110 mg/dl, thus fulfilling the latest criteria for
impaired fasting glucose. If NCEP/ATP III metabolic
syndrome criteria were employed [26], then the
diagnosis of metabolic syndrome might be
established in 12 control subjects (37.5%). In the
control group there was, however, no correlation
between concentrations of MMPs and age or BMI.
Insulin resistance indices (HOMA, IRI) in the control
group are presented in Table IB. Concentrations of
both MMP-2 and MMP-9 are presented in Table II
and Figures 1A-B. The levels of both MMP-2 and
MMP-9 were lower in subjects with type 2 DM 
(219 ±62 ng/ml vs. 305 ±63 ng/ml and 716 ±469
ng/ml vs. 1285 ±470 ng/ml, for MMP-2 and
MMP-9, respectively, p < 0.05). In diabetic subjects
there was a negative correlation between MMP-2
and age (rs = –0.55, p = 0.008) and between 
MMP-9 and HbA1c (rs = 0.47, p = 0.03, n = 15, Figure
2B) and BMI (rs = –0.47, p = 0.03, n = 22). In
a multivariate model those two covariates (HbA1c
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and BMI) explained, however, only 34% of MMP-9
variability. There was also a positive correlation
between MMP-2 and glucose levels on admission
(rs = 0.81, p = 0.002, Figure 2A). There was also
a negative correlation between MMP-9 and BMI 
(rs = –0.47, p = 0.03). This was, however, no longer
significant (p = 0.16), when both BMI and HbA1c
were included in a multivariate analysis. In subjects
Group n Mean ± SEM Median Min MaxV alue of p
Age [years] Diabetes 22 56.65 ±3.59  54 28 80 0.01
Controls 32 31.84 ±2.81 36 18 65
Body mass index [kg/m2] Diabetes 22 31.84 ±0.99 31.6 23.8 41.4 0.07
Controls 32 35.17 ±1.63 35.5 19.6 56.9
Triglycerides [mg/dl] Diabetes 22 184.8 ±28.4 127.0 44.0 542.0 0.26
Controls 32 130.9 ±9.2 125.0 57.0 306.0
Cholesterol total [mg/dl] Diabetes 22 197.1 ±9.3 204.0 116.0 298.0 0.49
Controls 32 194.7 ±9.0 189.0 127.0 408.0
Cholesterol-LDL [mg/dl] Diabetes 22 117.1 ±8.8 110.0 70.0 189.0 0.81
Controls 32 121.4 ±7.8 113.5 59.00 295.0
Cholesterol-HDL [mg/dl] Diabetes 22 37.2 ±2.2 37.0 25.0 64.0 0.003
Controls 32 46.3 ±2.2 43.0 23.00 83.0
Table IA. Descriptive statistics for demographic characteristics and the levels of lipid parameters in the diabetes and
control group. Value of p represents the significance level of the Mann-Whitney test for comparison of  distributions
between groups
Mean Median Min MaxS DS E
HOMA 2.71 2.12 0.85 7.07 1.75 0.31
IRI 1.23 1.26 0.57 1.82 0.35 0.06
Table IB. Descriptive statistics for insulin resistance indices HOMA [23] and Insulin Resistance Index (IRI) [24, 25] in
the control group (n = 32)
n Mean Med Min MaxS D S E V alue of pP vs. Contr
MMP-2 Ad 22 219 203 138 377 62 13 – – 0.000008
[ng/ml] 15 208 195 155 377 55 14 Ad vs. Ds 0.55
8 191 195 157 227 26 9 –
Ds 15 195 202 107 260 50 13 – 0.0000004
8 221 237 139 260 40 14 Ds vs. 3m 0.26
3m 8 199 203 131 259 41 14 Ad vs. 3m 0.69 0.00006
MMP-9 Ad 22 716 640 230 2080 460 98 –
[ng/ml] 15 730 530 230 2080 542 140 Ad vs. Ds 0.08 0.00005
8 854 700 280 2080 560 198 Ad vs. Ds 0.02
Ds 15 529 480 200 980 243 63 – 0.000001
8 489 445 200 980 284 101 Ds vs. 3m 0.81
3m 8 500 510 230 840 235 83 Ad vs. 3m 0.02 0.00005
Table II. Descriptive statistics for the levels of plasma concentrations of matrix metalloproteinases (MMP-2 and
MMP-9) in the diabetes group – at admission (Ad, n = 22), discharge (Ds, n = 15) and after 3 months of follow-up 
(n = 8). Value of p represents the significance level of the appropriate paired test for comparison of mean values of
these characteristics in different time intervals for 15 or 8 individuals, respectively. In the additional column ‘P vs
Contr’, significance levels for comparisons with the control group (n = 32) are presented (t-test). Corresponding
values in the control group were 305 ±63 ng/ml and 1285 ±470 ng/ml, for MMP-2 and MMP-9, respectively. Statistical
significance of the measured parameters did not change after application of the ANOVA Friedman test for comparison
of MMP-2 and MMP-9 at different time intervals for 8 individuals with type 2 diabetes, where measurements were
performed at all three time points (p = 0.22, and p = 0.02, for MMP-2 and MMP-9, respectively)
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with type 2 DM there was no difference in MMP-2
at the time of admission vs. discharge (n = 15) from
hospital and after 3 months (n = 8). In contrast,
there was a trend towards lower MMP-9 levels at
time of hospital discharge (p = 0.08, n = 15). 
In 8 subjects with MMP-9 data at all three time-
points, the concentrations of MMP-9 were lower at
discharge and after 3 months in comparison to
levels at admission (MMP-9: 854 ±560 ng/ml at
admission and 500 ±235 ng/ml after 3 months 
(p = 0.02, n = 8, Table II, Figures 3A-B). This was
accompanied by a significant decrease in HbA1c
concentrations in those patients from 9.77 ±1.76%
to 8.36 ±1.54% (p < 0.01, n = 8, Figure 3C). In
controls there was no correlation between both
MMP-2 and MMP-9 and HOMA (r = –0.11, p = 0.54,
r = 0.27, p = 0.14, for MMP-2 and MMP-9, respec  -
tively), or IRI (r = –0.03, p = 0.85, r = 0.18, p = 0.33,
for MMP-2 and MMP-9, respectively). Transient
hyperglycaemia during OGTT did not influence
serum MMP-2 concentrations but resulted in
a significant fall in MMP-9 at 0 vs. 120 min of OGTT,
both when examined by t-test and by Friedman’s
rank ANOVA (MMP-9 1675 ±419 ng/ml at 0 min of
OGTT vs. 1276 ±452 ng/ml at 120 min of OGTT, 
p = 0.047 (Friedman’s rank ANOVA, Table III, 
Figures 4A-B).
Discussion
Despite the multitude of data on the potential
relationship between MMPs and cardiovascular
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Figure  1A.  Box and whisker plot for plasma
concentrations of MMP-2 in the controls (n = 32) and
subjects with type 2 diabetes (n = 22). Significantly
lower values in diabetes in comparison to controls
are marked by asterisk: * (p ≤ 0.0001)
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Figure  1B.  Box and whisker plot for plasma
concentrations of MMP-9 in the controls (n = 32) and
subjects with type 2 diabetes (n = 22). Significantly
lower values in diabetes in comparison to controls
are marked by asterisk: * (p ≤ 0.0001)
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Figure 2A. Correlation between serum concentrations
of MMP-2 and glucose in subjects with type 2 dia  -
betes on admission to hospital (n = 15) (Pearson’s
method: r = 0.750, p = 0.0014, Spearman rank
correlation method: rs = 0.81, p = 0.002)
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Figure 2B. Correlation between serum concentrations
of MMP-9 and HbA1c in subjects with type 2 diabetes
(n = 22, Pearson’s method: r = 0.517, p = 0.014,
Spearman rank correlation method: rs = 0.47, p = 0.03)
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disease, and despite the well-known fact of
significantly increased incidence and prevalence of
cardiovascular disease in people with type 2
diabetes, the role of MMPs in development of both
micro- and macrovascular complications has only
recently started to be investigated. Contrary to our
expectations our study demonstrated lower
concentrations of both MMP-2 and MMP-9 in
subjects with type 2 diabetes. Current literature
data on this issue are conflicting, with some studies
reporting raised blood concentrations of MMPs in
subjects with type 2 DM [27, 28], while some
studies demonstrated either no difference in
plasma MMPs between subjects with and without
type 2 DM [29], or lower concentrations of MMPs
in patients with type 2 DM, i.e. similar results to
our data [30]. In our opinion, several factors might
have contributed to decreased concentrations of
MMPs in our patients with diabetes. These factors
might include effects of medications commonly
used by subjects with type 2 diabetes, such as
statins, ACE inhibitors/AT-II blockers, calcium
channel blockers and acetylsalicylic acid. Statins
and fibrates are the most common agents used in
therapy of hyperlipidaemia in diabetes. These
agents exert anti-inflammatory and antioxidant
effects, improve endothelial function and stabilise
atherosclerotic plaque via modulation of extra  -
cellular matrix homeostasis and a decrease in
concentrations and activity of metalloproteinases
and their inhibitors [31], the same being largely also
applicable to ACE inhibitors and AT-II blockers [32].
Calcium channel blockers reduce the secretion of
MMP-9 and TIMP-1 by macrophages [33], while
acetylsalicylic acid blocks the cyclooxygenase,
decreases the synthesis of prostaglandins and then
controls the pathological activation of MMPs [34,
35]. These effects of medication render the issue of
adequate subject matching in controls vs. diabetic
patients extremely difficult as according to the
current standards virtually every patient with type 2
diabetes qualifies for treatment with statins, while
the great majority require ACE-inhibitors/AT-II
blockers as well as other agents (e.g. calcium
channel blockers) for treatment of hypertension
and/or renoprotection. Though not the primary
subject of the study it is of interest to note that our
subjects treated with insulin or sulfonylurea-
metformin combinations (all of whom also received
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Figure  3A.  Box and whisker plot for serum
concentrations of MMP-2 in diabetic patients at
different time intervals: admission, discharge from
hospital and after three months (n = 8)
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Figure  3B.  Box and whisker plot for serum
concentrations of MMP-9 in diabetic patients at
different time intervals: admission to hospital, discharge
from hospital and after three months (n = 8).
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statins, ACE-inhibitors ± calcium channel blockers
and aspirin) tended to have lower concentrations
of MMP-2 (mean 190 ng/ml vs. 252 ng/ml) and
MMP-9 (572 ng/ml vs. 990 ng/ml) than those on
metformin ± acarbose, who received less
medication. In our opinion the issue of quantitative
effects of medications on serum MMPs has only
recently begun to be investigated and warrants
a separate study. 
Despite these limitations our data support
a possibility that prolonged hyperglycaemia might
be related to increased activity of some MMPs,
given the positive correlation between serum 
MMP-9 concentrations and HbA1c. This is also
supported by a trend towards a decline in serum
MMP-9 concentrations at the time of discharge
from hospital (when glycaemic control was better)
as well as by a significant decrease in MMP-9 at
three months post-discharge, accompanied by a fall
of HbA1c. This hypothesis might be supported 
by some animal data as in dogs chronic hyper  -
glycaemia abolishes development of coronary
collateral vessels by increasing MMP-9 activity and
angiostatin expression [36].
The issue of the effects of acute hyperglycaemia
upon MMPs appears to be complex. First, there
seems to be differential regulation of MMPs, as
there was a change of MMP-9, but not MMP-2 at
120 min of OGTT. Selective decline of MMP-9, but
not MMP-2, raises a possibility of differential
regulation of MMPs in response to acute changes
in glycaemia. There are very few data on changes
of MMPs in response to acute, i.e. short-term
changes of glycaemia. Sampson et al. [30] report
a fall in soluble adhesion molecules (VCAM-1, 
ICAM-1, E-selectin), but no change in plasma levels
of MMP-3 and MMP-9 at 90 min after a 75-g oral
glucose tolerance test. This differs from our data,
though we note that in our subjects the decline in
serum MMP-9 was significant only at 120 min, and
not at 60 min of OGTT, so a longer period of
hyperglycaemia might be required to observe
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OGTT n Mean ± SEM   Median Min MaxV alue of p
MMP-2 0’ 8 367±13 357 335 454 0.88
[ng/ml] 60’ 8 357 ±21 376 263 420
120’ 8 355 ±23 339 265 475
MMP-9 0’ 8 1675 ±148 1600 1180 2320 0.047
[ng/ml] 60’ 8 1421 ±212 1485 450 2390
120’ 8 1276 ±156 1245 570 2070
Table III. Descriptive statistics for the levels of plasma concentrations of matrix metalloproteinases (MMP-2 and
MMP-9) during oral glucose tolerance test (OGTT) in the control group. Value of p represents the significance level
of the ANOVA Friedman test for comparison of these characteristics in different OGTT time intervals for 8 individuals
OGTT 0 min OGTT 60 min OGTT 120 min
Figure  4A.  Box and whisker plot for serum
concentrations of MMP-2 during 75 g oral glucose
tolerance test (OGTT) in the control group (n = 8,
Friedman’s rank ANOVA)
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Figure  4B.  Box and whisker plot for serum
concentrations of MMP-9 during OGTT in the control
group (n = 8). Significantly lower values in 120 min 
in comparison to 0 min are marked by asterisk: 
* (p = 0.047, Friedman’s rank ANOVA)
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significant changes in plasma/serum MMP-9
concentrations. Interestingly, Polhill et al. [37]
demonstrated differences between the effects of
short vs. longer periods of hyperglycaemia. The
authors exposed human renal cortical fibroblasts
to short-term (2 h) hyperglycaemia (15 mmol/l),
three times a day over 72 h. There was an increase
in extracellular matrix accumulation association
with increased tissue inhibitor of matrix
metalloproteinase that would in turn lead to
decreased activity of MMPs. In contrast, sustained
exposure to hyperglycaemia (15 mmol/l) resulted
in increased MMP-2 and MMP-9 activities. It should
be mentioned, however, that in some studies the
authors employed very high glucose concentrations
in order to demonstrate increased MMPs activity
in blood vessels, rather than the levels typically
observed in clinical practice. For instance, in the
study of Death et al. [38], glucose levels were
around 25 mmol/l (450 mg/dl), while such
concentrations are observed only in extremely
poorly controlled patients with type 2 DM on the
verge of hyperosmolar non-ketotic hyperglycaemia. 
Another issue that warrants discussion is the
possible relationship between MMPs and insulin.
Our data do not provide convincing support for
a significant direct effect of either acute or chronic
hyperinsulinaemia on serum MMPs. In our control
group there was no correlation between serum
MMP concentrations and either HOMA or IRI.
Previously we had also failed to demonstrate
a correlation between MMP-2 or MMP-9 and
fasting insulin in women with polycystic ovary
syndrome [39]. Other authors report either lack of
a direct correlation between MMP-2 or MMP-9 and
HOMA [40], or just a relatively weak correlation
between plasma MMP-9 and fasting insulin 
(r2 = 0.16, p = 0.04) [41]. There is also evidence that
insulin infusion might exert opposite effects to
those induced by hyperglycaemia, as it exerts
antioxidant and anti-inflammatory effects [42].
Insulin also improves nitric oxide production and
results in improved blood circulation to ischaemic
areas [42]. Hence, though an unfavourable milieu
associated with metabolic syndrome might
promote increased activity of MMPs, insulin per se
is rather unlikely to play a crucial role in this
phenomenon. There are, however, studies that
demonstrated an increase in free MMP-2 and
MMP-9 (zymographic method) in aortic tissue of
male rats during euglycaemic-hyperinsulinaemic
clamp [43], or in monocytes of hyperinsulinaemic
and obese mice [44], the latter study contrasting
with the lack of increase in MMP activity in
monocytes in humans with type 2 DM [22]. 
The limitations of the study include a high 
drop-out rate among subjects with type 2 DM, 
who presented for evaluation at 3 months after
discharge, older age of our patients with type 2
diabetes, and the failure to account for all possible
effects of medications taken by our patients with
type 2 DM on serum concentrations of MMP-2 and
MMP-9. It would be, however, unethical to deprive
patients with type 2 DM of their vital medications,
such as statins or ACE inhibitors. We also believe
that the age difference between the groups per se
was unlikely to explain the observed differences in
MMP concentrations, given the lack of any
correlation between age and MMPs in the control
group.
In conclusion, our study demonstrated lower
levels of MMP-2 and MMP-9 in subjects with type 2
diabetes, the reasons for this phenomenon being
complex. Our results also suggest that MMP-9, in
contrast to MMP-2, may be more prone to possibly
inhibitory short-term effects of hyperglycaemia vs.
possibly stimulatory long-term effects of raised
glucose concentrations. Given the ample evidence
for a possible role of MMPs in cardiovascular
disease and diabetes, we postulate that further
research on larger groups of subjects might help to
elucidate the effects of hyperglycaemia and
hyperinsulinaemia upon the activity of matrix
metalloproteinases in humans.
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